aTyr Pharma reported a Q4 2025 net loss attributable to shareholders of USD 14.0 million, or USD 0.14 per share (basic and diluted), on no revenue, with R&D expenses of USD 10.9 million and G&A expenses of USD 3.9 million. For FY 2025, aTyr Pharma posted no revenue and a net loss attributable to shareholders of USD 74.1 million, or USD 0.80 per share, as R&D expenses totaled USD 60.2 million and G&A expenses were USD 17.6 million. Cash, cash equivalents, restricted cash and available-for-sale investments were USD 80.9 million as of Dec. 31, 2025. On the business update, aTyr Pharma said it is scheduled to meet with the FDA in mid-April 2026 in a Type C meeting to review Phase 3 EFZO-FIT results and determine the path forward for efzofitimod in pulmonary sarcoidosis; the trial did not meet its primary endpoint, but the 5.0 mg/kg dose showed benefit on multiple pre-specified measures at week 48, including KSQ-Lung (p=0.0479) and Fatigue Assessment Scale (p=0.0226), and was well-tolerated. The company also said its Phase 2 EFZO-CONNECT study of efzofitimod in systemic sclerosis-related ILD remains on track to complete enrollment in H1 2026, and highlighted a poster presentation on ATYR0101 and a Journal of Biological Chemistry publication on a NRP2/PLXNA1 bispecific antibody.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603051601PRIMZONEFULLFEED9666083) on March 05, 2026, and is solely responsible for the information contained therein.
Comments